Bronx, New York Clinical Trials
A listing of Bronx, New York clinical trials actively recruiting patient volunteers.
Found 554 clinical trials
Acne study trial
hello Acne study trial Hello!Acne study trial Hello!Acne study trial Hello!Acne study trial Hello!Acne study trial Hello!
- 6 views
- 04 Aug, 2023
- 1 location
Safety Pharmacokinetics and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation
Primary Objectives: Phase 1: To characterize the safety and tolerability of isatuximab in kidney transplant candidates. Phase 2: To evaluate the efficacy of isatuximab in desensitization of patients awaiting kidney transplantation. Secondary Objectives: Phase 2: To characterize the safety profile of isatuximab in kidney transplant candidates. To characterize the pharmacokinetic …
- 0 views
- 12 Nov, 2020
- +2 other locations
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B Dose Expansion Part B: To assess the …
- 0 views
- 04 Dec, 2020
- +7 other locations
- 0 views
- 23 Jan, 2023
- 1 location
Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata (APACCO) updated
Apremilast mediates its clinical effect through the cAMP-PKA-NFkappaB pathway which results in a clinical picture changes to a decrease of all signs of inflammation.Due to the NFkappaB mediated chronical inflammation in the pathogenesis of acne conglobata, a treatment with Apremilast seems to be an effective option.In this study, treatment with …
- 0 views
- 14 Mar, 2022
- +3 other locations
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.
- 0 views
- 14 Mar, 2022
- +1 other locations
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI test
The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.
- 0 views
- 14 Mar, 2022
- +1 other locations